To identify new biomarkers for biochemical recurrence (BCR) of prostate adenocarcinoma.
Introduction
Prostate cancer is the second most common malignancy, with an estimated 1.1 million new cases in the world according to the GLOBOCAN 2012 report (http://globocan.iarc.fr). In the USA, prostate cancer is the second leading cause of cancer deaths in men, and 26 120 men were estimated to die from prostate cancer in 2016 [1] . More than 95% of all diagnosed cases of prostate cancer are prostate adenocarcinoma [2] . Prognostic factors of prostate adenocarcinoma serve to estimate the risk for disease progression and to determine treatment strategies [3] . Preoperative serum PSA level, Gleason score, pathological stage, and resection margin status are considered the most important prognosticators for recurrence and prostate cancer-specific mortality [3] . However, clinicopathological factors, such as PSA level, Gleason score and pathological stage, and imaging studies cannot provide a definite prediction of patient outcome. Biomarkers that are predictive of tumour aggressiveness and easily applicable can help make a more accurate therapeutic decision, particularly at the time of initial diagnosis, compared with clinical and histological variables [4] .
Although numerous promising biomarkers have been introduced that exhibit good discriminatory power, few can be assessed using easily applied methods, such as immunohistochemistry (IHC), in clinical practice [5] [6] [7] .
The Cancer Genome Atlas (TCGA) is a public project led by the National Institutes of Health. TCGA has a goal of the discovery of major cancer-causing genomic alterations by creating a comprehensive atlas of cancer genomic profiles by systematising cancer genome data. To date, TCGA research teams have constructed large cohorts of >30 cancers using large-scale genome sequencing and integrated multidimensional analyses with phenotypic data. Coincidence studies of individual cancer types, as well as comprehensive pan-cancer analyses, have extended current knowledge of tumours [8, 9] . TCGA provides clinicopathological, RNA, and protein data of each cancer. Reverse-phase protein array (RPPA) is a high-throughput antibody-based technique with a procedure similar to that of Western blots [10] [11] [12] . RPPA data can be coupled with clinical and mRNA expression data to consolidate the evidence of protein expression. RPPA data can also be confirmed using IHC [13] .
In the present study, we analysed multi-dimensional proper omics data of prostate adenocarcinoma from the database of TCGA and sought to identify adequate IHC candidate targets to discriminate between patients with prostate adenocarcinoma according to the predictive recurrence of the tumours. We also confirmed expression of the candidates using IHC in a cohort of patients with prostate adenocarcinoma using available formalin-fixed paraffinembedded (FFPE) tumour tissues.
Patients and Methods

TCGA mRNA and Protein Expression Data
We directly downloaded clinical information, level 3 RNA sequencing (RNA-seq) and RPPA data of 500 patients with prostate adenocarcinoma from the data portal of TCGA (https://tcga-data.nci.nih.gov) on 28 January 2016. Gene expression levels using RNA-Seq by Expectation Maximization (RSEM) normalised read counts were used for mRNA expression analysis. Text files of clinical data, mRNA, and protein obtained from each dataset were combined according to TCGA case identification. In all, 155 molecules with both mRNA and protein expression data were analysed in this study. The combined dataset was listed in chronological order and separated into two groups: 191 patients were included in the discovery set, and 309 patients were included in the validation set. The datasets were subgrouped and analysed according to the grade groups (GGs) or recurrence-free survival (RFS). The GGs were based on the Gleason score resulting in five prognostically distinct subgroups: GG1, Gleason score ≤6; GG2, Gleason score = 7 (3 + 4); GG3, Gleason score = 7 (4 + 3); GG4, Gleason score = 8 (3 + 5), (4 + 4), or (5 + 3); and GG5, Gleason score 9-10 [14] . Biochemical recurrence (BCR) was defined as a serum PSA level of ≥0.2 ng/mL on two consecutive occasions after achieving an undetectable PSA level after radical prostatectomy [15] . [14, 16, 17] .
A TMA with 0.6-mm diameter cores was generated from the collected tumour tissue blocks, and three representative cores were included for each case. This clinical study was approved by the Institutional Review Board of the AMC (2011-499).
IHC
We attempted to validate the expression of all candidates from TCGA data with FFPE tumour tissues by IHC, but we could not evaluate cyclin B1 (CCNB1), paxillin (PXN), and X-ray repair cross complementing 5 (XRCC5) due to poor staining quality. The IHC detection of BIM, transferrin, RAF1 and dishevelled segment polarity protein 3 (DVL3) was conducted using specific antibodies. Sections from the TMA blocks were immunostained using the Ventana Benchmark XT automated staining system (Ventana Medical Systems, Tucson, AZ, USA) according to the manufacturer's protocol. Detailed antibody information and IHC conditions are summarised in Table S1 .
The expression of all proteins as assessed by IHC was scored according to the visual intensity and the extent of staining. The protein expression level was quantitated using the Hscore, which was calculated by multiplying the intensity and extent of each staining [18, 19] .
Statistical Analyses
Statistical analyses were performed using R3.0.2 (R Development Core Team, Vienna, Austria). The relationships between groups were compared using the chi-squared test or Student's t-test. The Kaplan-Meier method with the log-rank test and multivariate Cox proportional hazards regression model were used to evaluate the effect of the classifier on patient survival. Multivariate survival analysis using Cox's regression model with a stepwise backward elimination approach was performed to acquire prognostic significant factors (P < 0.1) from features. To assess discrimination capability by expression levels of proteins for RFS in the final Cox proportional hazards regression model, Harrell's bias corrected concordance index (C-index) with models was refitted 1 000 times with the bootstrap resampling technique for the acquisition of the CIs. All statistical tests were twosided, and statistical significance was defined as P < 0.05.
Results
Searching for Candidates in TCGA Data
We performed the log-rank test using RFS to determinate the threshold for subgrouping of the cases according to the GGs. Among 191 cases of the TCGA discovery set, the numbers of cases in GG1, GG2, GG3, GG4, and GG5 were 12, 85, 50, 20, and 24, respectively. The RFS was statistically distinctive in ≤GG2 vs ≥GG3 (P = 0.002), ≤GG3 vs ≥GG4 (P < 0.001), and ≤GG4 vs ≥GG5 (P = 0.002) (Table S2) . Subgrouping was performed as ≤GG3 vs ≥GG4 because this grouping showed the lowest P-value, and were designated as the lower-risk and higher-risk groups for BCR. RFS was longer in the lower-risk group than in the higher-risk group, based on Kaplan-Meier survival analysis (P < 0.001) (Fig. 1 ). To identify candidate molecules implicated with clinicopathological and prognostic features of patients with prostate adenocarcinoma, RNA-seq mRNA and RPPA protein expression of molecules were compared in each subgroup using the Student's t-test. Seven molecules, including CCNB1, DVL3, PXN, RAF1, transferrin, XRCC5, and BIM, had differential mRNA and protein expression between the lower-risk and higher-risk groups in the TCGA discovery set (Table 1 ).
In the TCGA validation set, CCNB1, DVL3, transferrin, XRCC5 and BIM mRNA and protein were differently expressed between the two groups, and all of these genes exhibited increased expression in the higher-risk group compared with the lower-risk group, which is similar to that observed in the discovery set (Table 1) . However, PXN and RAF1 protein expression lacked statistical significance.
Confirming Protein Expression of the AMC Confirmation Cohort
The mean H-score of DVL3 was higher in only the higherrisk group compared with the lower-risk group (P = 0.011) ( Table 1) . DVL3 (P = 0.009) and BIM (P = 0.023) expression was associated with the RFS of patients, and the threshold Hscores were 88 and 15, respectively (Table 2 and Fig. 2A ). RAF1 and transferrin had no correlation with the mean Hscore or the RFS of patients between the groups. As summarised in Table 3 , DVL3 positivity, i.e. H-score >88, was found in 67.3% (249/370), and BIM positivity, i.e. Hscore >15, was found in 39.5% (156/395) of all patients. DVL3 expression was significantly associated with the presence of high PSA levels (P = 0.030), resection margin involvement (P = 0.045), and BCR (P = 0.006). High Gleason score, i.e. ≥GG4, exhibited a marginal relationship with DVL3 positivity (P = 0.055). However, DVL3 expression was not statistically related to age, pT stage, lymphovascular invasion (LVI), lymph node (LN) metastasis, or patient death. BIM expression was significantly associated with high PSA levels (P = 0.022), LVI (P = 0.012), and BCR (P = 0.012). However, BIM expression was not significantly related to age, GG, pT stage, resection margin involvement, LN metastasis, or patient death.
Prognostic Implications of DVL3 and BIM Expression in the AMC Confirmation Cohort DVL3 positivity was associated with shorter RFS in the univariate survival analysis [hazard ratio (HR) 1.73; P = 0.010], but its statistical significance was lost when the (Table S3 ). In the lower-risk group, patients with DVL3 positivity had reduced RFS compared with those with DVL3 negativity by both Kaplan-Meier (P = 0.012; Fig. 2B ) and univariate Cox regression (HR 2.00, P = 0.014) analyses. Importantly, the multivariate Cox regression model comprising DVL3, age, PSA level, and pT stage in the lowerrisk group confirmed that DVL3 was a significant independent predictor of poor RFS (HR 1.80, P = 0.040) ( Table 4 ). The C-index of the Cox regression model comprising age, PSA level, and pT stage was 0.756 (95% CI 0.708-0.804). When DVL3 was added to the model, the Cindex was increased by 0.049, and the C-index was 0.805 (95% CI: 0.755-0.855). In the higher-risk group, patients with DVL3 positivity were not associated with RFS (P = 0.850; Fig. 2C ).
BIM positivity was associated with reduced RFS by univariate survival analysis (P = 0.023 via Kaplan-Meier analysis; HR 1.48, P = 0.024 via Cox regression analysis), but its statistical significance was lost when the multivariate Cox regression model included all patients (Fig. 3A and Table S4 ), similar to DVL3. In addition, BIM expression was not related to RFS in the lower-risk or the higher-risk groups (Fig. 3B and C) .
Discussion
The incidence of clinically diagnosed prostate cancer rapidly increased worldwide from the late 1980s to the early 2000s as H-score ranged from 0 to 300. The mean H-scores of DVL3, RAF1, transferrin, and BIM were 126, 188, 19, and 43, respectively, in all patients in the AMC confirmation cohort. Table 2 The best thresholds of H-score determined using IHC reflecting BCR in patients in the AMC confirmation cohort.
Molecules
Threshold (H-score) P 
346
© 2017 The Authors BJU International © 2017 BJU International a result of the adoption of serum PSA screening (http://glob ocan.iarc.fr). Several molecular alterations based on the pathognomonics of the tumours have markedly improved the management of patients and have even change the classification of tumour subtypes. For example, the detection of activating mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain in patients with advanced non-small-cell lung cancer has allowed clinicians to efficiently apply EGFR-targeted therapy [20] . Renal cell carcinoma that harbours gene fusions involving two members i.e. transcription factor E3 (TFE3) and transcription factor EB (TFEB), of the micropthalmia (MiT) family of transcription factors exhibits unique clinicopathological features and is subtyped in a distinctive entity [21] . In prostate cancer, several molecular aberrations, such as alterations of the androgen receptor or erythroblast transformation-specific (ETS)-related gene (ERG) overexpression, are commonly regarded as potential biomarkers, but their predictive or prognostic values remain disputed. Androgen signalling aberrations occur later in tumour progression, and the prognostic value of transmembrane protease, serine 2 (TMPRSS2)-ERG is limited in radical prostatectomy specimens [22, 23] . Therefore, efforts to discover novel biomarkers that are clinically applicable are still ongoing, particularly to prevent over-or under-treatment in patients with localised prostate adenocarcinoma who undergo radical prostatectomy.
In the present study, we investigated new prognostic biomarker candidates for tumour recurrence. All the candidate molecules are involved in cancer progression regulating proliferation, mitosis, DNA repair, invasion, metastasis, angiogenesis, molecular transportation and apoptosis. CCNB1 regulates mitosis, especially G2/M phase. In prostate cancer, knockdown of tripartite motif 59 (TRIM59), which is a regulator of transcription factors and tumour suppressors, inhibited cell proliferation and colony formation. The cell cycle regulators cell division cycle 25A (CDC25A), cyclin dependent kinase 1 (CDK1), and CCNB1 were also decreased by TRIM59 short hairpin RNA-mediated knockdown [24] . XRCC5 functions in the repair of DNA double-strand breaks. Variable number tandem repeats polymorphism in the XRCC5 promoter is associated with altered risk of breast cancer in breast cancer type 1 susceptibility protein (BRCA1)+ and breast cancer type 2 susceptibility protein (BRCA2)+ carriers [25] . Glucose deprivation mediated stress increased the expression of nuclear Ku encoded by XRCC5 or XRCC6 and resistance to radiation-induced oxidative stress in HT29 and DU145 human prostate cancer cells [26] .
We showed that DVL3 expression correlated with important clinicopathological variables, such as serum PSA level and Gleason score. DVL3 was also related to poor RFS.
Particularly, in the patients with GG1-GG3 prostate adenocarcinoma, DVL3 was an independent prognostic factor for BCR according to the multivariate Cox model comprising age, PSA level, and pT stage with a high C-index. Currently, no definite and easily applicable biomarkers for BCR, in addition to age, serum PSA level, and several histological variables, such as pT stage, resection margin involvement, and high-grade prostatic intraepithelial neoplasia, have been suggested in this group of patients [3, 7] . Consequently, DVL3 information may aid in clinical decision-making, such as follow-up interval or implementing adjuvant treatment. In addition, in the multivariate Cox regression model of all cases, DVL3 was not an independent predictive factor, potentially due to the correlation with resection margin involvement, PSA level, and Gleason score. Dysregulation of Wnt signalling has been shown in several types of cancers, including prostate cancer [27] . DVLs are dishevelled segment polarity proteins that are a homologue of the Drosophila dishevelled (dsh) gene and encode a cytoplasmic phosphoprotein that regulates cell proliferation by Wnt signalling [27] . DVL3, a member of DVLs family and plays an important role in signal amplification in the canonical Wnt/b-catenin cascade during tumorigenesis [28] . In addition, DVL3 transduces extracellular polarity cues and integrates a myriad of extracellular and intracellular inputs to induce intracellular cytoskeleton rearrangements and impact cell behaviours as a member of the non-canonical Wnt/planar cell polarity pathway [29] . Also, DVL3 regulates cancer progression, invasion, metastasis, and angiogenesis, and the overexpression of DVL3 correlates with progression in patients with non-small-cell lung cancer [30] . Recently, DVL3 was suggested to mediate resistance to the inhibition of IGF receptor-1 (IGF-IR), which is a promising new therapeutic target for several cancers including breast and prostate cancers in preclinical and early trials, by mediating the IGF- Moreover, sensitivity to IGF-IR inhibition was specifically enhanced by genetic or pharmacological blockade of DVL3 [31] . These results suggest that DVL3 may have predictive value or be a novel therapeutic target in addition to having prognostic value.
Transferrin is involved in cellular iron transportation by receptor-mediated endocytosis. Recently, transferrin has been used as an efficient carrier of therapeutic molecules to overcome drug resistance in many cancers such as breast cancer, lung cancer or glioblastoma [32] [33] [34] . BIM acts as an apoptotic activator and its expression is associated with good prognosis in colon cancer [35] . In the present study, the expression of both transferrin and BIM were increased in the higher-risk group compared to the lower-risk group and the implications should be investigated in further studies.
We analysed TCGA data by integrating clinical, mRNA and protein expression to overcome the limited number of cohorts. RPPA is a protein array of a micro-or nano-scaled dot-blot platform that is printed to a substrate to simultaneously measure protein expression levels in a large number of biological samples in a quantitative manner [36] . Human epidermal growth factor receptor 2 (HER2) scores based on IHC were reproduced using RPPA with breast cancer FFPE tissues, and programmed death-ligand 1 (PD-L1) mRNA expression exhibited a positive correlation with RPPA data in lung adenocarcinoma [13, 37] . However, the list of evaluated molecules by RPPA in TCGA were limited to only a few hundred proteins. Thus, there is a possibility that a valuable candidate has been missed. The present study can be extended when new TCGA RPPA data for new molecules are added. In addition, the results of DVL3 IHC should be validated with biopsy or whole resection specimen because the expression pattern may vary depending on the type of specimen and heterogeneity of the tumour.
We identified candidate biomarkers of BCR of prostate adenocarcinoma by integrating the RPPA and mRNA data from TCGA. Then, these biomarkers were validated using IHC in a prostate adenocarcinoma confirmation cohort, and both DVL3 and BIM were associated with BCR. Importantly, DVL3 may be a novel and easily applicable recurrence predictor of localised prostate adenocarcinoma. 
